Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Journal article (11)
- Doctoral Thesis (11)
Keywords
- BDNF (22) (remove)
Institute
- Institut für Klinische Neurobiologie (9)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (7)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Neurologische Klinik und Poliklinik (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Graduate School of Life Sciences (1)
- Institut für Anatomie und Zellbiologie (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
- Neurochirurgische Klinik und Poliklinik (1)
In der Behandlung neuropathischer und anderer chronischer Schmerzen werden trizyklische Antidepressiva bereits mit Erfolg eingesetzt, die nebenwirkungsärmeren SSRI zeigen jedoch nur einen mäßigen Erfolg. In dieser Studie gingen wir der Frage nach, inwieweit 5-HTT -/- Mäuse, die als Modell einer lebenslangen Behandlung mit SSRI gelten, in einem chronisch entzündlichen Schmerzmodell ein anderes Schmerzverhalten zeigen als Wild-typen und ob sich auf neuronaler Ebene durch das Ausschalten des 5-HT Transporters Ursachen für ein geändertes Schmerzverhalten finden lassen. Von besonderem Interesse war dabei auch, welche Rolle 5-HT in der peripheren Schmerzvermittlung zukommt. Mit standardisierten Testverfahren wurden die 5-HTT -/- Mäuse und Wildtypmäuse nach i.pl. Injektion von CFA auf zwei Schmerzqualitäten hin untersucht. Die Schmerzschwelle für taktile Reize wurde mit von Frey Haaren bestimmt, zur Testung der Hitzehyperalgesie wurde eine Infrarotwärmequelle benutzt. Anschließend wurden an dem Gewebe immunhistochemische Analysen durchgeführt und mittels HPLC der Gehalt an 5-HT in verschiedenen Gewebeproben bestimmt. Es konnte gezeigt werden, dass Mäuse mit dem Genotyp 5-HTT -/- gegenüber dem Wildtyp von einer durch CFA-Injektion induzierten Hitzehyperalgesie weitgehend unbeeinträchtigt bleiben. Gleichzeitig bestand bei den KO-Mäusen im Vergleich zu den Wildtypen eine deutlichere Abnahme der Hautinnervation sowie eine stärker ausgeprägte Verletzung von DRG-Neuronen, entsprechend einer erhöhten neuronalen Vulnerabilität gegenüber CFA. Im Gewebe der KO-Mäuse fand sich durchweg weniger 5-HT als bei Wildtypen, in DRG-Neuronen der KO-Mäuse war weiterhin weniger BDNF detektierbar. Wir postulieren, dass für die reduzierte Hitzehyperalgesie bei den KO-Mäusen unter anderem der geringere Gewebespiegel von 5-HT und damit folglich in einer Art Ursachen-Wirkungskette auch die geringeren Gewebespiegel von BDNF und 5-HIAA mit ihren entsprechenden Auswirkungen verantwortlich sind. 5-HTT -/- Mäuse als Modell für eine lebenslange Behandlung mit SSRI sind also nicht nur wie kürzlich beschrieben im neuropathischen Schmerzmodell, sondern auch in einem chronisch entzündlichen Schmerzmodell weitgehend vor einer Hitzehyperalgesie geschützt. Unter der Berücksichtigung dieser Daten sollte daher der Einsatz von SSRI in der Behandlung chronischer Schmerzen erneut überprüft werden.
Alzheimer's disease (AD), the most common cause of dementia in the elderly, is a neurodegenerative disorder associated with neurovascular dysfunction and cognitive decline. While the deposition of amyloid β peptide (Aβ) and the formation of neurofibrillary tangles (NFTs) are the pathological hallmarks of AD-affected brains, the majority of cases exhibits a combination of comorbidities that ultimately lead to multi-organ failure. Of particular interest, it can be demonstrated that Aβ pathology is present in the hearts of patients with AD, while the formation of NFT in the auditory system can be detected much earlier than the onset of symptoms. Progressive hearing impairment may beget social isolation and accelerate cognitive decline and increase the risk of developing dementia. The current review discusses the concept of a brain–ear–heart axis by which Aβ and NFT inhibition could be achieved through targeted supplementation of neurotrophic factors to the cochlea and the brain. Such amyloid inhibition might also indirectly affect amyloid accumulation in the heart, thus reducing the risk of developing AD-associated amyloid cardiomyopathy and cardiovascular disease.
Neurotrophin signaling via receptor tyrosine kinases is essential for the development and function of the nervous system in vertebrates. TrkB activation and signaling show substantial differences to other receptor tyrosine kinases of the Trk family that mediate the responses to nerve growth factor and neurotrophin-3. Growing evidence suggests that TrkB cell surface expression is highly regulated and determines the sensitivity of neurons to brain-derived neurotrophic factor (BDNF). This translocation of TrkB depends on co-factors and modulators of cAMP levels, N-glycosylation, and receptor transactivation. This process can occur in very short time periods and the resulting rapid modulation of target cell sensitivity to BDNF could represent a mechanism for fine-tuning of synaptic plasticity and communication in complex neuronal networks. This review focuses on those modulatory mechanisms in neurons that regulate responsiveness to BDNF via control of TrkB surface expression.
Background:
Memory reconsolidation is the direct effect of memory reactivation followed by stabilization of newly synthesized proteins. It has been well proven that neural encoding of both newly and reactivated memories requires synaptic plasticity. Brain derived neurotrophic factor (BDNF) has been extensively investigated regarding its role in the formation of synaptic plasticity and in the alteration of fear memories. However, its role in fear reconsolidation is still unclear; hence, the current study has been designed to investigate the role of the BDNF val66met polymorphism (rs6265) in fear memory reconsolidation in humans.
Methods:
An auditory fear-conditioning paradigm was conducted, which comprised of three stages (acquisition, reactivation, and spontaneous recovery). One day after fear acquisition, the experimental group underwent reactivation of fear memory followed by the extinction training (reminder group), whereas the control group (non-reminder group) underwent only extinction training. On day 3, both groups were subjected to spontaneous recovery of earlier learned fearful memories. The treat-elicited defensive response due to conditioned threat was measured by assessing the skin conductance response to the conditioned stimulus. All participants were genotyped for rs6265.
Results:
The results indicate a diminishing effect of reminder on the persistence of fear memory only in the Met-allele carriers, suggesting a moderating effect of the BDNF polymorphism in fear memory reconsolidation.
Conclusions:
Our findings suggest a new role for BDNF gene variation in fear memory reconsolidation in humans.
Neurotrophe Faktoren haben ein breites Aufgabenfeld und spielen eine wichtige Rolle als Überlebensfaktoren embryonaler Neurone, bei Proliferation und Differenzierung im Nervensystem sowie als Modulatoren synaptischer Plastizität. Im ersten Themenkomplex der vorliegenden Arbeit wurden neurotrophe Faktoren als Modulatoren synaptischer Plastizität und ihr Einfluß auf die BDNF-Regulation im Hippocampus untersucht. Dabei wurde zunächst das selbsthergestellte polyclonale BDNF-Immunserum für die Anwendung in der Immunhistochemie und im Western Blot optimiert, doch es konnten bezüglich BDNF keine Veränderungen in Hippocampi CNTF-defizienter Mäuse gegenüber Wildtyp-Tieren festgestellt werden. Die Ergebnisse der Voruntersuchungen, die im Hippocampus CNTF-defizienter Tiere verminderte BDNF-Level gezeigt hatten, konnten somit nicht verifiziert werden. Im Rahmen dieser Arbeit wurde an CNTF-defizienten Mäusen eine eingeschränkte LTP und LTD nachgewiesen. Zum besseren Verständnis der – laut LTP-Untersuchungen – veränderten Situation an der hippocampalen CA1-Synapse bei CNTF-defizienten Tieren wurden elektronenmikroskopische Bilder dieser Region angefertigt, deren Auswertung keine augenscheinlichen Unterschiede ergab. Im Stratum radiatum der CA1-Region war zudem keine spezifische CNTF-Färbung nachweisbar. Zur Klärung der Frage, ob es IGF-vermittelt nach Training zu hippocampaler BDNF-Hochregulation kommt, wurden Laufradexperimente mit wildtypischen und konditionalen IGF1-Rezeptor-knockout Mäusen durchgeführt und die jeweiligen BDNF-Level untersucht. Dabei wurde BDNF durch Laufradtraining in beiden Genotypen in ähnlichem Maße hochreguliert, was für alternative Wege der BDNF-Hochregulation spricht. Der zweite Themenkomplex befasste sich mit dem Einfluß neurotropher Faktoren auf die Proliferation und Differenzierung in Hippocampus und Cortex. BrdU-Inkorporationsexperimenten zeigten in der Körnerzellschicht des Gyrus dentatus gesteigerte Proliferationsraten bei CNTF-defizienten und CNTF&LIF-defizienten Mäusen, wobei LIF-defiziente Tiere keine veränderten Proliferationsraten zeigten. Untersuchungen an Kulturen cortikaler Vorläuferzellen bestätigten die Hypothese, wonach cortikale Vorläuferzellen zunächst Neurone bilden, die einen Faktor sezernieren, der auf die cortikalen Vorläuferzellen wirkt und sie zur Bildung von Astrozyten veranlasst. Es konnte gezeigt werden, dass CT-1 der Hypothese folgend in vitro und in vivo für die Einleitung der Astrozytogenese im Cortex verantwortlich ist.
The tropomysin receptor kinase B (TrkB), the receptor for the neurotrophin brain-derived neurotrophic factor (BDNF), plays an important role in neuronal survival, neuronal differentiation, and cellular plasticity. Conventionally, TrkB activation is induced by binding of BDNF at extracellular sites and subsequent dimerization of receptor monomers. Classical Trk signaling concepts have failed to explain ligand-independent signaling of intracellular TrkB or oncogenic NTRK-fusion proteins. The intracellular activation domain of TrkB consists of a tyrosine kinase core, with three tyrosine (Y) residues at positions 701, 705 and 706, that catalyzes the phosphorylation reaction between ATPγ and tyrosine. The release of cisautoinhibition of the kinase domain activates the kinase domain and tyrosine residues outside of the catalytic domain become phosphorylated. The aim of this study was to find out how ligand-independent activation of TrkB is brought about. With the help of phosphorylation mutants of TrkB, it has been found that a high, local abundance of the receptor is sufficient to activate TrkB in a ligand-independent manner. This self-activation of TrkB was blocked when either the ATP-binding site or Y705 in the core domain was mutated. The vast majority of this self-active TrkB was found at intracellular locations and was preferentially seen in roundish cells, lacking filopodia. Live cell imaging of actin dynamics showed that self-active TrkB changed the cellular morphology by reducing actin filopodia formation. Signaling cascade analysis confirmed that self-active TrkB is a powerful activator of focal adhesion kinase (FAK). This might be the reason why self-active TrkB is able to disrupt actin filopodia formation. The signaling axis from Y705 to FAK could be mimicked by expression of the soluble, cytosolic TrkB kinase domain. However, the signaling pathway was inactive, when the TrkB kinase domain was targeted to the plasmamembrane with the help of artificial myristoylation membrane anchors. A cancer-related intracellular NTRK2-fusion protein (SQSTM1-NTRK2) also underwent constitutive kinase activation. In glioblastoma-like U87MG cells, self-active TrkB kinase reduced cell migration. These constitutive signaling pathways could be fully blocked within minutes by clinically approved, anti-tumorigenic Trk inhibitors. Moreover, this study found evidences for constitutively active, intracellular TrkB in tissue of human grade IV glioblastoma. In conclusion, the data provide an explanation and biological function for selfactive, constitutive TrkB kinase domain signaling, in the absence of a ligand.
In the mammalian brain, the neurotrophin brain-derived neurotrophic factor (BDNF) has emerged as a key factor for synaptic refinement, plasticity and learning. Although BDNF-induced signaling cascades are well known, the spatial aspects of the synaptic BDNF localization remained unclear. Recent data provide strong evidence for an exclusive presynaptic location and anterograde secretion of endogenous BDNF at synapses of the hippocampal circuit. In contrast, various studies using BDNF overexpression in cultured hippocampal neurons support the idea that postsynaptic elements and other dendritic structures are the preferential sites of BDNF localization and release. In this study we used rigorously tested anti-BDNF antibodies and achieved a dense labeling of endogenous BDNF close to synapses. Confocal microscopy showed natural BDNF close to many, but not all glutamatergic synapses, while neither GABAergic synapses nor postsynaptic structures carried a typical synaptic BDNF label. To visualize the BDNF distribution within the fine structure of synapses, we implemented super resolution fluorescence imaging by direct stochastic optical reconstruction microscopy (dSTORM). Two-color dSTORM images of neurites were acquired with a spatial resolution of ~20 nm. At this resolution, the synaptic scaffold proteins Bassoon and Homer exhibit hallmarks of mature synapses and form juxtaposed bars, separated by a synaptic cleft. BDNF imaging signals form granule-like clusters with a mean size of ~60 nm and are preferentially found within the fine structure of the glutamatergic presynapse. Individual glutamatergic presynapses carried up to 90% of the synaptic BDNF immunoreactivity, and only a minor fraction of BDNF molecules was found close to the postsynaptic bars. Our data proof that hippocampal neurons are able to enrich and store high amounts of BDNF in small granules within the mature glutamatergic presynapse, at a principle site of synaptic plasticity.
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) affecting more than two million people worldwide. In MS, oligodendrocytes and myelin sheaths are destroyed by autoimmune-mediated inflammation, while remyelination is impaired. Recent investigations of post-mortem tissue suggest that Fibroblast growth factor (FGF) signaling may regulate inflammation and myelination in MS. FGF2 expression seems to correlate positively with macrophages/microglia and negatively with myelination; FGF1 was suggested to promote remyelination. In myelin oligodendrocyte glycoprotein (MOG)\(_{35–55}\)-induced experimental autoimmune encephalomyelitis (EAE), systemic deletion of FGF2 suggested that FGF2 may promote remyelination. Specific deletion of FGF receptors (FGFRs) in oligodendrocytes in this EAE model resulted in a decrease of lymphocyte and macrophage/microglia infiltration as well as myelin and axon degeneration. These effects were mediated by ERK/Akt phosphorylation, a brain-derived neurotrophic factor, and downregulation of inhibitors of remyelination. In the first part of this review, the most important pharmacotherapeutic principles for MS will be illustrated, and then we will review recent advances made on FGF signaling in MS. Thus, we will suggest application of FGFR inhibitors, which are currently used in Phase II and III cancer trials, as a therapeutic option to reduce inflammation and induce remyelination in EAE and eventually MS.
Background: There is increasing evidence that glial cells play a role in the pathomechanisms of mood disorders and the mode of action of antidepressant drugs.
Methods: To examine whether there is a direct effect on the expression of different genes encoding proteins that have been implicated in the pathophysiology of affective disorders, primary astrocyte cell cultures from rats were treated with two different antidepressant drugs, imipramine and escitalopram, and the RNA expression of brain-derived neurotrophic factor (Bdnf), serotonin transporter (5Htt), dopamine transporter (Dat), and endothelial nitric oxide synthase (Nos3) was examined.
Results: Stimulation of astroglial cell culture with imipramine, a tricyclic antidepressant, led to a significant increase of the Bdnf RNA level whereas treatment with escitalopram did not. In contrast, 5Htt was not differentially expressed after antidepressant treatment. Finally, neither Dat nor Nos3 RNA expression was detected in cultured astrocytes.
Conclusion: These data provide further evidence for a role of astroglial cells in the molecular mechanisms of action of antidepressants.